港股创新药指数再升级 银华基金创新药投资工具布局丰富

Core Viewpoint - The adjustment of the Guozheng Hong Kong Stock Connect Innovative Drug Index aims to enhance its investment value by excluding CXO companies and increasing the frequency of index adjustments, reflecting the latest trends in China's innovative drug industry [1][2]. Group 1: Index Adjustment Details - The sample selection criteria will now focus on companies whose main business involves the research and production of innovative drugs, excluding CXO services [1]. - The index will undergo quarterly adjustments, implemented on the next trading day following the second Friday of March, June, September, and December each year [1]. Group 2: Market Insights - The exclusion of CXO companies is expected to sharpen the index's focus on innovative drug manufacturers, which are seen as industry leaders reflecting the trend of domestic innovative drug companies going global [1][2]. - The innovative drug sector is currently experiencing a growth phase, with any quality innovative drug company potentially attracting capital through product upgrades, thereby boosting market valuations [2]. Group 3: Long-term Outlook - The long-term investment value of innovative drugs is supported by the industry's improving fundamentals, with significant growth in BD transaction amounts expected to continue [3]. - The recognition of R&D capabilities in the innovative drug sector has become a market consensus, indicating a shift from sporadic breakthroughs to a more comprehensive advancement [3]. Group 4: Recent Market Activity - The innovative drug sector has seen a continuous rise, with related ETFs attracting significant capital interest, indicating active trading sentiment [4]. - On July 29, the trading volume for the Silver Hua Fund's innovative drug ETF exceeded 707 million yuan, while the Hong Kong innovative drug ETF reached 2.73 billion yuan, reflecting strong investor engagement [4].